February 4, 2022

IVD devices: Extension of timelines for the application of Regulation (EU) 2017/746

Regulation (EU) 2022/112 of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices was published on January 25, 2022.

The new regulation amended Articles 110, 112, and 113, providing new timelines for the implementation of Regulation (EU) 2017/746. In particular, the term of validity of any certificates issued under the directive has been extended from May 27, 2024 to May 27, 2025.

The European Commission explained that “the IVD Regulation will apply from 26 May 2022 as scheduled. However, there is a serious shortage of notified body capacity, making it impossible for manufacturers to conduct the legally required conformity assessment procedures in time. Without any legislative action, there was a risk of significant disruption in the supply of various essential in vitro diagnostic medical devices on the market, affecting the diagnosis of patients and their access to relevant health care.”

In particular, devices for which the conformity assessment procedure pursuant to Directive 98/79/EC did not require the involvement of a notified body, for which a declaration of conformity was drawn up prior to May 26, 2022, in accordance with that directive, and for which the conformity assessment procedure pursuant to this regulation requires the involvement of a notified body, may be placed on the market or put into service until the following dates:

(a) May 26, 2025, for class D devices (higher risk devices, such as HIV or hepatitis tests);

(b) May 26, 2026, for class C devices (lower risk devices, such as certain influenza tests); and

(c) May 26, 2027, for class B and class A sterile devices (lower risk devices).

In any event, it is further specified that (i) the requirements of the regulation relating to post-market surveillance, market surveillance, vigilance, and registration of economic operators and devices shall apply to these devices; and (ii) the notified body that issued the relevant certificates shall continue to be responsible for the appropriate surveillance with regard to all applicable requirements relating to the devices it has certified.

Moreover, the application of certain requirements for devices manufactured and used in the same health institution (known as “in-house devices”) has been deferred for two years until May 2024. If, however, a health institution can prove that an equivalent device is not available on the market, the transitional period will end in May 2028.

No change is proposed for CE-marked devices that do not require notified body involvement under the IVD regulation, or for “new” devices, i.e., devices that have neither a notified body certificate nor a declaration of conformity under the current Directive 98/79/EC. For those devices, the IVD regulation will apply as of May 26, 2022, as originally planned.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
July 19, 2022
Guidelines for the implementation of the Electronic Health Record (EHR) to ensure dissemination, uniformity and accessibility of the EHR at national level now published in the Official Gazet...
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
Search by...
Search
Follow us on
Follow us on